Glycomic and Genomic Repercussion of Nebulisable Gal-3 Inhibitory Medical Device Treatment in Pulmonary Fibrosis

Project Information

Pulmonary Fibrosis

Grant agreement ID: 101033565

DOI 10.3030/101033565

EC signature date 12 April 2021

Start date 1 September 2022

End date 31 August 2025

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost € 257 561,28

EU contribution € 257 561,28

Coordinated by

UNIVERSITY OF GALWAY
Ireland